Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: The esprit trial: A randomized controlled trial

JAMA

Volumn 285, Issue 19, 2001, Pages 2468-2473

  O'Shea, J Conor ^a   Hafley, Gail E ^a   Greenberg, Sally ^b   Hasselblad, Vic ^a   Lorenz, Todd J ^b   Kitt, Miehael M ^b   Strony, John ^c   Tcheng, James E ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPTIFIBATIDE; FIBRINOGEN RECEPTOR; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; TREATMENT OUTCOME;

EID: 0035897706     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.285.19.2468     Document Type: Article

References (23)

1. Fuster V, Adams PC, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242-250.
2. Roe MT, Ohman EM, Maas AC, et al. Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. J Am Coll Cardiol. 2001;37:9-18.
3. Madan M, Berkowitz SD, Tcheng JE. Glycoprotein IIb/IIIa integrin blockade. Circulation. 1998;98: 2629-2635.
4. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation. 1998;98:2829-2835.
5. Hynes RO. Integrins: a family of cell surface receptors. Cell. 1987;48:549-554.
6. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69:11-25.
7. Jang U, Lincoff AM, Plow EF, Topol EJ. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol. 1994;24:1591-1601.
8. Phillips DR, Charo IF, Parisi LV, Fitzgerald LA. The platelet membrane glycoprotein IIb/IIIa complex. Blood. 1988;71:831-843.
9. Phillips DR, Charo IF, Scarborough RM. GP IIb-IIIa: the responsive integrin. Cell. 1991;65:359-362.
10. Charo IF, Kieffer N, Phillips DR. Platelet membrane glycoproteins. In: Colman RW, ed. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, Pa: JB Lippincott; 1994;489-507.
11. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-1559.
12. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet. 1997;349:1422-1428.
13. Ohman EM, Kleiman NS, Gacioch G, et al, for the IMPACT-AMI Investigators. Combined accelerated tissue-plasminogen activator and glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: results of a randomized, placebo-controlled dose ranging trial. Circulation. 1997;95: 846-854.
14. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436-443.
15. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000;356:2037-2044.
16. O'Shea JC, Madan M, Cantor WJ, et al. Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention. Am Heart J. 2000;140:834-839.
17. Topol EJ, Mark DB, Lincoff AM, et al, for the EPISTENT Investigators. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. Lancet. 1999; 354:2019-2024.
18. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/ IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
19. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
20. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87-92.
21. Abdelmeguid AE, Topol EJ. The myth of the myocardial 'infarctlet' during percutaneous coronary revascularization procedures. Circulation. 1996;94: 3369-3375.
22. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998;31:241-251.
23. Gibson C, Cohen D, Cohen E, et al. Eptifibatide improves coronary flow reserve following stent placement: an ESPRIT substudy [abstract]. Circulation. 2000; 102:11-366.